Skip to main content
Premium Trial:

Request an Annual Quote

Boehringer Ingelheim, Cenix in RNAi Research Deal

NEW YORK (GenomeWeb News) — Cenix BioScience will support Boehringer Ingelheim with RNAi-focused contract research services for its therapeutic drug programs under a new agreement, Cenix said today.

Cenix will apply its knowledge combining high throughput applications of RNAi-based gene silencing with phenotypic analysis in what will be a genome-scale screen using cultured human cells. Cenix will use microscopy-based assays it developed to complement proprietary assays developed by Boehringer Ingelheim to generate information about the cellular functions and loss-of-function phenotypes of analyzed genes.

Financial terms of the agreement were not released.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.